Posts by Antonia Palmer
DFMO is an interesting drug, and one that is currently being considered for a future clinical trial in Canada for children with neuroblastoma. There is a great deal to understand about this drug – both in how it works and the process for opening up a clinical trial in Canada.
In May 2015, neuroblastoma families became increasingly concerned about the use of G-CSF in treatment due to emerging research findings. This article reviews that research in hopes of providing some clarity.
The science and understanding of MIBG therapy for high-risk neuroblastoma continues to evolve and change. This article reviews past research, current practices and future directions of the treatment.
Your personal accountings of life tell a story and everyone’s numbers paint a different picture. This is an account of one 7-year-old boy in the battle against neuroblastoma cancer and what his numbers look like.
Neuroblastoma Canada interviews two authors from the CCRA’s report on the current state of financial investment into pediatric cancer research in Canada.
Navigating the options available for relapsed treatment is incredibly difficult and is done without a set of established and well-entrenched guidelines.
June 10-19, 2013 is International Neuroblastoma Awareness Week. A week dedicated to raise awareness about neuroblastoma cancer around the world.
The chemotherapeutic drugs used during stem-cell transplant for high-risk neuroblastoma appear to be changing under the Children’s Oncology Group (COG) protocol.
In 2012, the Children’s Oncology Group (COG) Neuroblastoma Committee documented the important current and future research being done to further understand this perplexing disease.
A new post on the NB Globe website provides a detailed look at MYCN amplification in neuroblastoma and the emergence of a new therapy called BET bromodomain inhibition.